Cellenkos is a series b startup based in United States. 1 investor tracked on Brouky Intelligence. Data sourced from Brouky Intelligence.
About
Cellenkos is a clinical-stage biotechnology company focused on developing and commercializing novel T-regulatory (Treg) cell therapies to treat autoimmune and inflammatory disorders.
Stage
series-b
Investors
1
See full investor history, risk signals & comparable companies
Brouky tracks 15,000+ startups with funding rounds, risk analysis, and AI-powered investor matching.
Subscribe to Brouky